PMID- 11408221
OWN - NLM
STAT- MEDLINE
DCOM- 20011004
LR  - 20181221
IS  - 0066-4804 (Print)
IS  - 1098-6596 (Electronic)
IS  - 0066-4804 (Linking)
VI  - 45
IP  - 7
DP  - 2001 Jul
TI  - Effect of famciclovir on herpes simplex virus type 1 corneal disease and 
      establishment of latency in rabbits.
PG  - 2044-53
AB  - Famciclovir (FCV) is efficacious in the treatment of acute herpes zoster and 
      recurrent genital infections but has not been used to treat ocular herpes simplex 
      virus (HSV) infections. We evaluated the efficacy of orally administered FCV in 
      treating HSV-1 epithelial keratitis and determined its effects on the 
      establishment of latency and subsequent reactivation. Rabbits were inoculated 
      with HSV-1 strain 17 syn+ and treated twice daily with increasing concentrations 
      of FCV (60 to 500 mg/kg of body weight). This resulted in a significant, 
      dose-dependent improvement in keratitis scores, as well as prolonged survival. 
      Regardless of the dose of drug used, all groups exhibited the high rates of 
      spontaneous and induced reactivation characteristic of 17syn+. The efficacy of 
      250 mg of FCV per kg was also compared to topical treatment with 1% 
      trifluorothymidine (TFT). Although TFT treatment was more effective at reducing 
      eye disease, FCV-treated rabbits had a better survival rate. Real-time 
      quantitative PCR analysis of rabbit trigeminal ganglia (TG) demonstrated that FCV 
      significantly reduced the HSV-1 copy number compared to that after treatment with 
      TFT or the placebo but not in a dose-dependent manner. In summary, oral FCV 
      treatment significantly reduces the severity of corneal lesions, reduces the 
      number of HSV-1 genomes in the TG, improves survival, and therefore may be 
      beneficial in reducing the morbidity of HSV keratitis in the clinic.
FAU - Loutsch, J M
AU  - Loutsch JM
AD  - Department of Ophthalmology, LSU Eye Center, Louisiana State University Health 
      Sciences Center, New Orleans, Louisiana 70112-2234, USA. jlouts@lsuhsc.edu
FAU - Sainz, B Jr
AU  - Sainz B Jr
FAU - Marquart, M E
AU  - Marquart ME
FAU - Zheng, X
AU  - Zheng X
FAU - Kesavan, P
AU  - Kesavan P
FAU - Higaki, S
AU  - Higaki S
FAU - Hill, J M
AU  - Hill JM
FAU - Tal-Singer, R
AU  - Tal-Singer R
LA  - eng
GR  - R01 EY006311/EY/NEI NIH HHS/United States
GR  - F32 EY006996/EY/NEI NIH HHS/United States
GR  - EY06986/EY/NEI NIH HHS/United States
GR  - F32 EY006986/EY/NEI NIH HHS/United States
GR  - EY06996/EY/NEI NIH HHS/United States
GR  - EY06311/EY/NEI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Antimicrob Agents Chemother
JT  - Antimicrobial agents and chemotherapy
JID - 0315061
RN  - 0 (Antiviral Agents)
RN  - 452-06-2 (2-Aminopurine)
RN  - QIC03ANI02 (Famciclovir)
RN  - RMW9V5RW38 (Trifluridine)
SB  - IM
MH  - 2-Aminopurine/analogs & derivatives/pharmacology/*therapeutic use
MH  - Acute Disease
MH  - Administration, Oral
MH  - Administration, Topical
MH  - Animals
MH  - Antiviral Agents/pharmacology/*therapeutic use
MH  - Corneal Diseases/*drug therapy/mortality/virology
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Famciclovir
MH  - Herpes Simplex/*drug therapy/mortality/virology
MH  - Herpesvirus 1, Human/drug effects
MH  - Keratitis, Herpetic/drug therapy/mortality
MH  - Rabbits
MH  - Trifluridine/pharmacology/therapeutic use
MH  - Trigeminal Ganglion/virology
MH  - Viral Load
MH  - Virus Latency/*drug effects
PMC - PMC90598
EDAT- 2001/06/16 10:00
MHDA- 2001/10/05 10:01
PMCR- 2001/07/01
CRDT- 2001/06/16 10:00
PHST- 2001/06/16 10:00 [pubmed]
PHST- 2001/10/05 10:01 [medline]
PHST- 2001/06/16 10:00 [entrez]
PHST- 2001/07/01 00:00 [pmc-release]
AID - 0790 [pii]
AID - 10.1128/AAC.45.7.2044-2053.2001 [doi]
PST - ppublish
SO  - Antimicrob Agents Chemother. 2001 Jul;45(7):2044-53. doi: 
      10.1128/AAC.45.7.2044-2053.2001.